Cargando…
Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
Most prostate cancers (PCas) are classified as acinar type (conventional) adenocarcinoma which are composed of tumor cells with luminal differentiation including the expression of androgen receptor (AR) and prostate-specific antigen (PSA). There are also scattered neuroendocrine (NE) cells in every...
Autores principales: | Lipianskaya, Julia, Cohen, Alexa, Chen, Clark J, Hsia, Elaine, Squires, Jill, Li, Zhen, Zhang, Yaqun, Li, Wei, Chen, Xufeng, Xu, Hua, Huang, Jiaoti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104077/ https://www.ncbi.nlm.nih.gov/pubmed/24589459 http://dx.doi.org/10.4103/1008-682X.123669 |
Ejemplares similares
-
Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014) -
Serum lipid profiles and aggressive prostate cancer
por: Li, Yanjing, et al.
Publicado: (2015) -
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022) -
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023) -
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
por: Edlind, Merritt P, et al.
Publicado: (2014)